Immuron Share Price - IMRN

0.00 (0.0%)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Immuron Ltd IMRN NASDAQ Depository Receipt
  Price Change Change Percent Stock Price Low Price High Price Open Price Previous Close Last Traded
0.00 0.0% 10.97 0.00 0.00 0.00 10.97 07:16:34
Bid Price Ask Price Spread Spread % News
10.76 11.00 0.24 2.18% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume
4 365  10.97  4,004 3,614,459
Last Trade Time Type Quantity Stock Price Currency
08:00:04 formt 344  10.97 USD

Immuron Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
 60.60M 5.52M 5.52M  -  - -0.90 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
-  - 0.00% - -

more financials information »

News Immuron

Date Time Source Heading
7/29/202006:29Edgar (US Regulatory)Report of Foreign Issuer (6-k)
7/24/202006:08Edgar (US Regulatory)Report of Foreign Issuer (6-k)
7/23/202012:45GlobeNewswire Inc.Immuron Limited Announces Closing of $20.0 Million..
7/23/202008:14Edgar (US Regulatory)Report of Foreign Issuer (6-k)
7/23/202006:03Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)
7/21/202009:11Edgar (US Regulatory)Statement of Ownership (sc 13g)
7/21/202008:45GlobeNewswire Inc.Immuron Announces $20.0 Million Registered Direct Offering
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

IMRN Historical

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.
1 Month0.
3 Months0.
6 Months0.
1 Year0.
3 Years0.
5 Years0.

Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's lead product candidate, IMM-124E, is a proprietary immunomodulator agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200810 12:38:12